Private Advisor Group LLC Grows Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Private Advisor Group LLC grew its stake in Humacyte, Inc. (NASDAQ:HUMA) by 232.7% in the first quarter, Holdings Channel.com reports. The firm owned 317,624 shares of the company’s stock after acquiring an additional 222,144 shares during the quarter. Private Advisor Group LLC’s holdings in Humacyte were worth $988,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in HUMA. Tower Research Capital LLC TRC increased its stake in shares of Humacyte by 261.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock worth $26,000 after acquiring an additional 6,504 shares during the last quarter. Whittier Trust Co. of Nevada Inc. acquired a new stake in Humacyte during the fourth quarter worth about $28,000. Victory Capital Management Inc. purchased a new position in Humacyte during the fourth quarter worth about $29,000. China Universal Asset Management Co. Ltd. boosted its holdings in Humacyte by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock valued at $34,000 after purchasing an additional 9,325 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC purchased a new stake in shares of Humacyte in the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Up 12.8 %

Humacyte stock opened at $6.45 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 8.37 and a current ratio of 8.37. The firm has a 50 day moving average price of $6.14 and a 200 day moving average price of $4.32. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $9.97. The company has a market capitalization of $768.07 million, a PE ratio of -6.23 and a beta of 1.51.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, May 10th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Research analysts expect that Humacyte, Inc. will post -0.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Brady W. Dougan sold 271,518 shares of Humacyte stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total value of $1,982,081.40. Following the completion of the transaction, the director now owns 4,559,140 shares in the company, valued at $33,281,722. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Brady W. Dougan sold 271,518 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $7.30, for a total value of $1,982,081.40. Following the sale, the director now directly owns 4,559,140 shares in the company, valued at $33,281,722. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 358,630 shares of Humacyte stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $7.08, for a total value of $2,539,100.40. Following the completion of the transaction, the chief executive officer now owns 4,830,658 shares of the company’s stock, valued at $34,201,058.64. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. Insiders own 23.10% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on HUMA shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a report on Tuesday, July 2nd. Benchmark reaffirmed a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Tuesday, July 2nd. Finally, Piper Sandler reissued a “neutral” rating and set a $4.00 price objective on shares of Humacyte in a research report on Tuesday, March 26th.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.